Joseph Hawkins, MD
Endocrinology · Fresno, CANPI 1841296894
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $412,542 of the $476,667 with a category attached, or 86.5%. 43 manufacturers reported payments, led by Amgen at 32.4% of the total. Reporting peaked in 2019 at $170,007 and has fallen 64.8% since, to $59,834 in 2025. Among endocrinology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,221 payments — averaging $390.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$154K
- Novo Nordisk$148K
- Lilly USA, LLC$109K
- AstraZeneca$38K
- Radius Health, Inc.$14K
- AbbVie$8K
- plus $6K from 37 others
What the payments were for
- Consulting fees$5000%
- Speaking & faculty fees$412,54287%
- Travel & lodging$38,1988%
- Food & beverage$25,1665%
- Education$2020%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$93,821
- Ozempic$88,407
- EVENITY$78,402
- Prolia$57,404
- FARXIGA$34,409
- RYBELSUS$29,474
- Tresiba$18,540
- Tymlos$13,069
- Synthroid$7,486
- Xultophy 100/3.6$2,210
- BYDUREON$2,150
- t:slim X2 insulin pump$125
- t-slim insulin pump$121
- RETEVMO$108
- FreeStyle Libre$107
- DEXCOM G7 GSS (161)$107
How this compares
$476,667 in reported general payments places this provider in the 95th percentile of 58 endocrinology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 51 | $93,538 |
| ForteoTeriparatide | 14 | $58,377 |
| SynthroidLevothyroxine Sodium | 467 | $54,573 |
| MounjaroTirzepatide | 31 | $46,850 |
| FarxigaDapagliflozin Propanediol | 42 | $45,887 |
| JardianceEmpagliflozin | 12 | $18,539 |
| Nutropin Aq NuspinSomatropin | 12 | $16,329 |
| Tresiba Flextouch U-200Insulin Degludec | 16 | $13,604 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 11 | $9,721 |
| Testosterone | 42 | $8,228 |
| VascepaIcosapent Ethyl | 12 | $3,994 |
| Estradiol | 52 | $3,563 |
| Levothyroxine Sodium | 255 | $3,219 |
| Novolog FlexpenInsulin Aspart | 11 | $3,020 |
| Liothyronine Sodium | 25 | $1,883 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCForteo, Mounjaro | $108,797 | $105,22745 claims |
| Novo NordiskOzempic | $147,858 | $93,53851 claims |
| AbbVieSynthroid, Armour Thyroid | $8,402 | $56,453478 claims |
| AstraZenecaFarxiga | $38,050 | $45,88742 claims |
| Boehringer IngelheimJardiance | $869 | $18,53912 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $178 | $9,72111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 58 endocrinology providers in California.
Other endocrinology in Fresno
- Minh MachBurbank$559K
- Michael BushBeverly Hills$380K
- Shawna WeislerBurbank$45K
- Ashiq PatelLancaster$32K
- Paul AzerBeverly Hills$25K
- Michael TranAnaheim$16K
- Samuel MayedaOrange$11K
- Daniel KaplanSan Leandro$8K
- Amy van BuiMission Viejo$8K
- Sandeep ChaudharyLaguna Hills$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.